SA517382016B1 - تركيب صيدلي لعلاج أمراض الجهاز الهضمي - Google Patents

تركيب صيدلي لعلاج أمراض الجهاز الهضمي Download PDF

Info

Publication number: SA517382016B1
Authority: SA; Saudi Arabia
Prior art keywords: sucralfate; particle size; pharmaceutical composition; ranitidine; bismuth
Prior art date: 2015-01-30

Application number

SA517382016A

Other languages

Arabic (ar)

English (en)

Inventor

وو لي جون

هو جو يونغ

Original Assignee

.دايوونج فارماسوتيكال كو.، ليمتد

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-01-30

Filing date

2017-07-29

Publication date

2021-03-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA517382016(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-07-29 Application filed by .دايوونج فارماسوتيكال كو.، ليمتد filed Critical .دايوونج فارماسوتيكال كو.، ليمتد

2021-03-18 Publication of SA517382016B1 publication Critical patent/SA517382016B1/ar

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 37
208000018522 Gastrointestinal disease Diseases 0.000 title abstract description 5
239000002245 particle Substances 0.000 claims abstract description 121
229960004291 sucralfate Drugs 0.000 claims abstract description 95
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims abstract description 95
229960000620 ranitidine Drugs 0.000 claims abstract description 63
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims abstract description 61
239000003814 drug Substances 0.000 claims abstract description 60
229960004645 bismuth subcitrate Drugs 0.000 claims abstract description 29
ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 claims abstract description 29
239000004480 active ingredient Substances 0.000 claims abstract description 14
229910052797 bismuth Inorganic materials 0.000 claims description 37
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 37
238000009826 distribution Methods 0.000 claims description 29
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
239000004372 Polyvinyl alcohol Substances 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 10
229920002451 polyvinyl alcohol Polymers 0.000 claims description 10
239000011248 coating agent Substances 0.000 claims description 8
230000033228 biological regulation Effects 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 2
210000001035 gastrointestinal tract Anatomy 0.000 claims 2
101100386518 Caenorhabditis elegans dbl-1 gene Proteins 0.000 claims 1
241000196324 Embryophyta Species 0.000 claims 1
239000000470 constituent Substances 0.000 claims 1
239000013563 matrix tablet Substances 0.000 claims 1
230000001681 protective effect Effects 0.000 claims 1
239000003826 tablet Substances 0.000 claims 1
239000011800 void material Substances 0.000 claims 1
229940079593 drug Drugs 0.000 abstract description 57
238000002360 preparation method Methods 0.000 abstract description 32
239000000203 mixture Substances 0.000 abstract description 27
238000009472 formulation Methods 0.000 abstract description 9
229940000425 combination drug Drugs 0.000 abstract 1
238000012360 testing method Methods 0.000 description 53
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 28
238000000034 method Methods 0.000 description 24
239000002994 raw material Substances 0.000 description 10
230000000052 comparative effect Effects 0.000 description 8
230000036470 plasma concentration Effects 0.000 description 8
230000008859 change Effects 0.000 description 7
239000000890 drug combination Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000008187 granular material Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
238000013112 stability test Methods 0.000 description 6
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
239000001863 hydroxypropyl cellulose Substances 0.000 description 5
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
238000005259 measurement Methods 0.000 description 5
238000010258 microfractionation Methods 0.000 description 5
238000002156 mixing Methods 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
-1 ranitidine compound Chemical class 0.000 description 5
239000007787 solid Substances 0.000 description 5
101100346656 Drosophila melanogaster strat gene Proteins 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000001174 ascending effect Effects 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000008213 purified water Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
208000007107 Stomach Ulcer Diseases 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
238000010835 comparative analysis Methods 0.000 description 3
238000005194 fractionation Methods 0.000 description 3
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
238000000227 grinding Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
230000000704 physical effect Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
235000010413 sodium alginate Nutrition 0.000 description 3
239000000661 sodium alginate Substances 0.000 description 3
229940005550 sodium alginate Drugs 0.000 description 3
239000008107 starch Substances 0.000 description 3
229940032147 starch Drugs 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
238000003860 storage Methods 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
229920001353 Dextrin Polymers 0.000 description 2
239000004375 Dextrin Substances 0.000 description 2
229920002907 Guar gum Polymers 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
229920002774 Maltodextrin Polymers 0.000 description 2
239000005913 Maltodextrin Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
235000019425 dextrin Nutrition 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000003107 drug analog Substances 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
208000000718 duodenal ulcer Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
235000013312 flour Nutrition 0.000 description 2
208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
238000007429 general method Methods 0.000 description 2
239000000665 guar gum Substances 0.000 description 2
235000010417 guar gum Nutrition 0.000 description 2
229960002154 guar gum Drugs 0.000 description 2
239000008172 hydrogenated vegetable oil Substances 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229940035034 maltodextrin Drugs 0.000 description 2
238000000691 measurement method Methods 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
239000012046 mixed solvent Substances 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
208000000689 peptic esophagitis Diseases 0.000 description 2
239000008196 pharmacological composition Substances 0.000 description 2
229920000193 polymethacrylate Polymers 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920003124 powdered cellulose Polymers 0.000 description 2
235000019814 powdered cellulose Nutrition 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000283707 Capra Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
238000001159 Fisher's combined probability test Methods 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000167880 Hirundinidae Species 0.000 description 1
101000574016 Homo sapiens Pre-mRNA-processing factor 40 homolog B Proteins 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229920003072 Plasdone™ povidone Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
102100025820 Pre-mRNA-processing factor 40 homolog B Human genes 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
229910052785 arsenic Inorganic materials 0.000 description 1
238000011953 bioanalysis Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000012812 general test Methods 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
229940046813 glyceryl palmitostearate Drugs 0.000 description 1
230000036449 good health Effects 0.000 description 1
239000008202 granule composition Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 1
229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
WXDJHDMIIZKXSK-UHFFFAOYSA-N iodine dioxide Inorganic materials O=I=O WXDJHDMIIZKXSK-UHFFFAOYSA-N 0.000 description 1
230000001788 irregular Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000007561 laser diffraction method Methods 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
230000010399 physical interaction Effects 0.000 description 1
229960000540 polacrilin potassium Drugs 0.000 description 1
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000011160 research Methods 0.000 description 1
238000000790 scattering method Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229960003885 sodium benzoate Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000008279 sol Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000005496 tempering Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
239000003643 water by type Substances 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SA517382016A 2015-01-30 2017-07-29 تركيب صيدلي لعلاج أمراض الجهاز الهضمي SA517382016B1 (ar)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
KR20150015339		2015-01-30
KR1020150147513A KR101583452B1 (ko)	2015-01-30	2015-10-22	위장질환 치료용 의약 조성물
PCT/KR2016/000935 WO2016122226A2 (fr)	2015-01-30	2016-01-28	Composition pharmaceutique pour le traitement de maladies gastro-intestinales

Publications (1)

Publication Number	Publication Date
SA517382016B1 true SA517382016B1 (ar)	2021-03-18

Family

ID=55169799

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SA517382016A SA517382016B1 (ar)	2015-01-30	2017-07-29	تركيب صيدلي لعلاج أمراض الجهاز الهضمي

Country Status (19)

Country	Link
EP (1)	EP3250199A4 (fr)
JP (1)	JP6419347B2 (fr)
KR (2)	KR101583452B1 (fr)
CN (1)	CN107205947B (fr)
AR (1)	AR105413A1 (fr)
CL (1)	CL2017001680A1 (fr)
CO (1)	CO2017006222A2 (fr)
EA (1)	EA032385B9 (fr)
EC (1)	ECSP17038599A (fr)
GE (2)	GEP20196941B (fr)
MA (1)	MA41432A (fr)
MX (1)	MX375765B (fr)
MY (1)	MY195824A (fr)
PE (1)	PE20171340A1 (fr)
PH (1)	PH12017550051A1 (fr)
SA (1)	SA517382016B1 (fr)
TW (1)	TWI635859B (fr)
UA (1)	UA116517C2 (fr)
WO (1)	WO2016122226A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101988479B1 (ko)	2017-10-11	2019-09-24	(주)휴럼	리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물
KR102286499B1 (ko) *	2018-04-13	2021-08-05	주식회사 삼양홀딩스	레날리도마이드를 포함하는 약제학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3874917T2 (de) *	1987-03-09	1993-03-04	Procter & Gamble	Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
US4990610A (en) *	1988-08-25	1991-02-05	Applied Analytical Industries, Inc.	Method for preparing high potency sucralfate
EP0403048A3 (fr) *	1989-06-14	1991-01-30	Warner-Lambert Company	Un modèle de structure de système craniomandibulaire humain
KR970006083B1 (ko) *	1992-01-22	1997-04-23	주식회사 대웅제약	위장질환 치료용 의약 조성물
CN1081921C (zh) *	1994-04-26	2002-04-03	中外制药株式会社	硫糖铝的熔融造粒制剂及其制造方法
JPH0879097A (ja) *	1994-09-01	1996-03-22	Matsushita Electric Ind Co Ltd	携帯無線機
KR970006083A (ko)	1995-07-06	1997-02-19	한승준	자동차용 카울부의 와이어 고정장치 취부구조
WO1999010000A1 (fr) *	1997-08-25	1999-03-04	The Procter & Gamble Company	Preparations combinees pour le traitement des douleurs du tractus gastro-intestinal superieur
WO2000078307A1 (fr) *	1999-06-21	2000-12-28	Daewoong Pharmaceutical Co., Ltd.	Preparation pharmaceutique a administration orale ayant une action therapeutique sur les troubles gastro-intestinaux, contenant de la ranitidine enrobee, du sous-citrate de bismuth et du sucralfate
JP2006076956A (ja) *	2004-09-10	2006-03-23	Taiyo Yakuhin Kogyo Kk	胃炎の治療・予防用配合剤
KR101617054B1 (ko) *	2008-07-01	2016-04-29	라이온 가부시키가이샤	고형내복제제
KR20110105223A (ko) *	2010-03-18	2011-09-26	일양약품주식회사	일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물
KR20140072673A (ko) *	2012-12-05	2014-06-13	(주)한국파비스제약	경구용 위장질환 치료를 위한 정제

2015
- 2015-10-22 KR KR1020150147513A patent/KR101583452B1/ko active Active
- 2015-12-31 KR KR1020150190850A patent/KR20160094268A/ko not_active Withdrawn
2016
- 2016-01-27 TW TW105102582A patent/TWI635859B/zh active
- 2016-01-27 MA MA041432A patent/MA41432A/fr unknown
- 2016-01-28 GE GEAP201614551A patent/GEP20196941B/en unknown
- 2016-01-28 EA EA201791458A patent/EA032385B9/ru not_active IP Right Cessation
- 2016-01-28 CN CN201680007680.7A patent/CN107205947B/zh active Active
- 2016-01-28 EP EP16743704.5A patent/EP3250199A4/fr not_active Withdrawn
- 2016-01-28 MX MX2017007567A patent/MX375765B/es active IP Right Grant
- 2016-01-28 PE PE2017001147A patent/PE20171340A1/es unknown
- 2016-01-28 UA UAA201707833A patent/UA116517C2/uk unknown
- 2016-01-28 JP JP2017540683A patent/JP6419347B2/ja active Active
- 2016-01-28 GE GEAP201814551A patent/GEP20186941B/en unknown
- 2016-01-28 WO PCT/KR2016/000935 patent/WO2016122226A2/fr not_active Ceased
- 2016-01-28 MY MYPI2017702737A patent/MY195824A/en unknown
- 2016-01-29 AR ARP160100272A patent/AR105413A1/es not_active Application Discontinuation
2017
- 2017-06-20 EC ECIEPI201738599A patent/ECSP17038599A/es unknown
- 2017-06-23 CO CONC2017/0006222A patent/CO2017006222A2/es unknown
- 2017-06-23 CL CL2017001680A patent/CL2017001680A1/es unknown
- 2017-07-25 PH PH12017550051A patent/PH12017550051A1/en unknown
- 2017-07-29 SA SA517382016A patent/SA517382016B1/ar unknown

Also Published As

Publication number	Publication date
MY195824A (en)	2023-02-22
EA032385B1 (ru)	2019-05-31
EP3250199A2 (fr)	2017-12-06
MX2017007567A (es)	2017-10-19
BR112017013857A2 (pt)	2018-02-27
KR101583452B9 (ko)	2022-05-02
JP6419347B2 (ja)	2018-11-07
CO2017006222A2 (es)	2017-09-20
CL2017001680A1 (es)	2018-01-12
MX375765B (es)	2025-03-07
EA201791458A1 (ru)	2017-11-30
EP3250199A4 (fr)	2018-08-08
PE20171340A1 (es)	2017-09-13
KR20160094268A (ko)	2016-08-09
PH12017550051A1 (en)	2018-01-29
JP2018503672A (ja)	2018-02-08
TWI635859B (zh)	2018-09-21
GEP20186941B (en)	2019-01-10
GEAP201814551A (en)	2018-08-27
KR101583452B1 (ko)	2016-01-11
MA41432A (fr)	2017-12-05
CN107205947B (zh)	2020-05-22
TW201639559A (zh)	2016-11-16
WO2016122226A2 (fr)	2016-08-04
UA116517C2 (uk)	2018-03-26
AR105413A1 (es)	2017-10-04
ECSP17038599A (es)	2017-09-29
EA032385B9 (ru)	2019-07-31
WO2016122226A3 (fr)	2016-09-15
CN107205947A (zh)	2017-09-26
GEP20196941B (en)	2019-01-10

Publication	Publication Date	Title
Vemula et al.	2015	Pharmacokinetics of colon-specific pH and time-dependent flurbiprofen tablets
KR101628937B1 (ko)	2016-06-09	콜린알포세레이트를 함유하는 정제 및 그 제조방법
CN113423390B (zh)	2023-05-23	阿法比星制剂及其制备方法
Vemula	2015	A novel approach to flurbiprofen pulsatile colonic release: formulation and pharmacokinetics of double-compression-coated mini-tablets
KR20170062470A (ko)	2017-06-07	아리모클로몰 제제
Bukara et al.	2016	In vivo performance of fenofibrate formulated with ordered mesoporous silica versus 2-marketed formulations: a comparative bioavailability study in beagle dogs
TW201306878A (zh)	2013-02-16	含有ｈｍｇ－ｃｏａ還原酶抑制劑及阿斯匹靈之藥學複合調配物
Venkateswarlu et al.	2016	Enhancement of loperamide dissolution rate by liquisolid compact technique
SA517382016B1 (ar)	2021-03-18	تركيب صيدلي لعلاج أمراض الجهاز الهضمي
WO2009039157A2 (fr)	2009-03-26	Formulations pharmaceutiques d'orlistat
WO2014065390A1 (fr)	2014-05-01	Procédé de suppression de dépôt d'efflorescences de menthol
JP2015193635A (ja)	2015-11-05	速溶性防湿フィルムコーティング製剤及びその製造方法
JP4549609B2 (ja)	2010-09-22	被覆固形催眠製剤
Setia et al.	2013	Development and optimization of enteric coated mucoadhesive microspheres of duloxetine hydrochloride using 32 full factorial design
CN108125918A (zh)	2018-06-08	依维莫司药物组合物
CN104644595B (zh)	2017-10-24	一种含有氯吡格雷的固体药物组合物
Pongjanyakul et al.	2012	Use of propranolol-magnesium aluminium silicate intercalated complexes as drug reservoirs in polymeric matrix tablets
Kadam et al.	2020	Formulation and evaluation of colon targeted enteric coated tablets of loperamide
JP2018090510A (ja)	2018-06-14	デュロキセチン塩酸塩を含む口腔内崩壊錠
EP3501609A1 (fr)	2019-06-26	Compositions pharmaceutiques comprenant de l'ibrutinib
Sravanthi et al.	2014	Formulation and evaluation of bi-layer floating tablets of amlodipine besylate and metoprolol succinate
CN103070850B (zh)	2015-08-05	具有良好体内行为的口服固体药物组合物
Sinha et al.	2010	Influence of operational variables in multi-particulate delayed release systems for colon-targeted drug delivery of celecoxib using extrusion spheronization
Patel	2012	Design, in vitro evaluation and in vivo studies of novel delayed release tablets of pantoprazole
JP2025105966A (ja)	2025-07-10	医薬組成物